AETHLON MEDICAL INC
For the period ended Mar 31, 2026. Filed Jun 10, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2026 · Filed Jun 10, 2026
AEMD$5.55+1.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
FOR THE YEARS ENDED MARCH 31, 2026 AND 2025
| Years Ended March 31, | ||
|---|---|---|
| 2026 | 2025 | |
| Cash flows from operating activities: | ||
| Net loss | $(7,151,469) | $(13,388,089) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 323,653 | 339,559 |
| Stock-based compensation | 278,547 | 415,234 |
| Non-cash lease expense | 294,026 | 281,208 |
| Warrant Inducement Expense | – | 4,612,862 |
| Changes in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 151,550 | 113,923 |
| Accounts payable and other current liabilities | (383,384) | (53,360) |
| Due to related parties | (511,315) | 33,131 |
| Net cash used in operating activities | (6,998,392) | (7,645,532) |
| Cash flows from investing activities: | ||
| Purchases of property and equipment | (3,704) | – |
| Cash used in investing activities | (3,704) | – |
| Cash flows from financing activities: | ||
| Tax withholding payments or tax equivalent payments for net share settlement of restricted stock units | (10,915) | (18,927) |
| Gross proceeds from the issuance of common stock and pre-funded warrants | 6,901,465 | 4,703,800 |
| Payments for offering costs related to equity issuance | (1,087,854) | (1,163,893) |
| Proceeds from exercise of warrants – standard terms | – | 2,054,940 |
| Proceeds from exercise of warrants – induced terms | 848,537 | 2,316,320 |
| Commission paid related to warrant inducement | – | (153,979) |
| Legal fees paid related to warrant inducement | – | (10,877) |
| Payments for deferred offering costs related to future equity issuance | (129,329) | – |
| Net cash provided by financing activities | 6,521,904 | 7,727,384 |
| Effect of Exchange Rate on Changes on Cash | 6,504 | (12,262) |
| Net (decrease) increase in cash and cash equivalents and restricted cash | (473,688) | 69,590 |
| Cash and cash equivalents restricted cash at beginning of year | 5,599,074 | 5,529,484 |
| Cash and cash equivalents and restricted cash at end of year | $5,125,386 | $5,599,074 |
| Supplemental information of non-cash investing and financing activities: | ||
| Issuance of shares under vested restricted stock units, net stock option exercises and unvested share issuance for services | $5 | $13 |
| Disposal of fully depreciated property | $14,628 | $350,670 |
| Warrant modification costs | $135,676 | $– |
| Deferred offering costs not yet paid | $81,656 | $– |
| Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets: | ||
| Cash and cash equivalents | $5,026,458 | $5,501,261 |
| Restricted cash | 98,928 | 97,813 |
| Cash and restricted cash | $5,125,386 | $5,599,074 |
Aethlon Medical, Inc. and Subsidiary
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.